Where Health Catalyst Stands With Analysts
Portfolio Pulse from Benzinga Insights
Health Catalyst (NASDAQ:HCAT) has received mixed analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, and 2 indifferent ratings. The average 12-month price target among 5 analysts is $12.2, which is a 12.86% decrease from the previous target of $14.00. The high target is $16.00 and the low target is $8.00.
November 13, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Health Catalyst has a new average price target of $12.2, reflecting a 12.86% decrease from the previous target, with mixed analyst ratings over the past quarter.
The mixed analyst ratings with a decrease in the average price target suggest a neutral short-term impact on HCAT's stock price. The ratings indicate uncertainty, which could lead to a wait-and-see approach among investors.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100